Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alimera Sciences, Inc. - Common Stock (NQ: ALIM )

5.540 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alimera Sciences, Inc. - Common Stock

< Previous 1 2 3 Next >
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock rose 45.44% to $5.58 during Monday's regular session. As of 12:30 EST, Vivos Therapeutics's stock is trading at a... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Alimera Sciences, inc (ALIM) Q2 2021 Earnings Call Transcript
ALIM earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Alimera Sciences Q2 Earnings
Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94%... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of... 
Via Benzinga
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
How Does Alimera Sciences's Debt Look?
Over the past three months, shares of Alimera Sciences (NASDAQ:ALIM) fell by 3.92%. Before we understand the importance of debt, let us look at how much debt Alimera... 
Via Benzinga
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
Alimera Sciences Inc (ALIM) Q1 2021 Earnings Call Transcript
ALIM earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
Recap: Alimera Sciences Q1 Earnings
Shares of Alimera Sciences (NASDAQ:ALIM) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 162.50% over the... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Week In Review: Sinopharm Transfers $4.6 Billion In Assets, Including Two COVID-19 Vaccines
Sinopharm Group will transfer six of its vaccine companies to Beijing Tiantan Biological Products. Two of the transferring companies have approved COVID-19 vaccines, and Sinopharma said a public... 
Via Talk Markets
Exposures COVID-19
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
10 Biggest Price Target Changes For Thursday
Raymond James lifted NVIDIA Corporation (NASDAQ: NVDA) price target from $700 to $750. NVIDIA shares rose 1.9% to $622.39 in pre-market trading. Barclays raised the price target... 
Via Benzinga
Alimera, Ocumension Ink Licensing Pact For Fluocinolone Acetonide Eye Implant In China
Ocumension Therapeutics has inked an exclusive license agreement for Alimera Sciences Inc's (NASDAQ: ALIM) 0.19mg fluocinolone acetonide... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback